Caris Diagnostics devises gene test for colon cancer patients

Phoenix-based Caris Diagnostics has developed a genetic test that can help identify colon cancer patients most likely to benefit from treatment with chemotherapy in tandem with tailored cancer drugs, such as ImClone Systems' Erbitux and Amgen's Vectibix. The combination of a test and a targeted medication shows the potential of personalized therapies in drug delivery, Caris CEO Dr. Robert Penny said.

View Full Article in:

Arizona Republic (Phoenix) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL